Clinical Trial Update: Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on ferriprox for iron overload and sickle cell disease/other anemias; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Overload
• Other Anemias
• Sickle Cell Disease

Drugs mentioned

• FERRIPROX (deferiprone)

Snippet

Sponsor: ApoPharma | Conditions: Iron Overload, Sickle Cell Disease | Phase 4 | Status: TERMINATED | Results posted: 2021-08-10